The Prospect and Challenges of Repurposing Established Drugs in Pulmonary Arterial Hypertension
<i>Pulmonary</i> arterial hypertension (PAH) is a progressive disorder caused by the narrowing of small blood vessels in the lungs, which, in the absence of therapies, leads to right heart failure and premature death. No cure for this devastating disorder is known. Current management the...
Saved in:
Main Authors: | Sila Ozlem Sener (Author), Rateep Nasim (Author), Talat Nasim (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach
by: Fatma Haddad, et al.
Published: (2023) -
Drug-induced pulmonary artery hypertension
by: O. D. Ostroumova, et al.
Published: (2022) -
Anthelmintics for drug repurposing: Opportunities and challenges
by: Seyed Ebrahim Alavi, et al.
Published: (2021) -
Prospects for repurposing CNS drugs for cancer treatment
by: Mohamed Abdelaleem, et al.
Published: (2019) -
Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
by: Allan K. N. Alencar, et al.
Published: (2017)